| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15130599 | IVTH | 0.00001 M | 0.00001 M | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:16962624 | IVTH | 0.00000001 - 0.000001 M | 0.00000003 - 0.000001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.000001 M | 0.00000003 - 0.000001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.000001 M | 0.00000003 - 0.000001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:18626888 | IVTH | 0.00000005 - 0.0001 M | 0.000004 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations |
| IVTH | 0.00000005 - 0.0001 M | 0.000004 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| PMID:19733639 | IVTH | 0.00000001 - 0.00001 M | 0.0000001 - 0.00001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.00001 M | 0.00000001 - 0.00001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.00001 M | 0.00001 M | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.00001 M | 0.00001 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.00001 M | 0.00001 M | Decreased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:20087668 | IVTH | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.0001 M | 0.0000003 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:20708073 | IVTH | 0.0000001 - 0.00003 M | 0.0000001 - 0.00003 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 - 0.00003 M | 0.0000001 - 0.00003 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.00003 M | 0.0000001 - 0.00003 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:21959537 | IVTH | 0.00000001 - 0.000003 M | 0.00000001 - 0.000003 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 - 0.000003 M | 0.0000001 - 0.000003 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:23616146 | IVTH | 0.000001 - 0.01 mmol/L | 0.0001 - 0.1 mmol/L | Decrease in cortisol levels | Neurological endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.01 mmol/L | 0.0001 - 0.1 mmol/L | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:24486430 | IVTH | 0.000001 - 0.000003 M | 0.000001 - 0.000003 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.000003 M | 0.000001 - 0.000003 M | Decreased estrogen levels | Reproductive endocrine-mediated perturbations | |
| PMID:25324206 | IVTH | 0.000001 M | 0.000001 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000003 M | - | No significant effects observed | - | |
| IVTH | 0.000003 M | 0.000003 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00003 M | 0.00003 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 M | 0.00001 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00003 M | 0.00003 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| PMID:26914364 | IVR | 5 mg/kg/day | 5 mg/kg/day | Nipple retention | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | - | No significant effects observed | - | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Nipple retention | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:33646749 | IVTH | 0.000001 M | 0.000001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:33983380 | IVR | 1 - 75 mg/kg/day | 1 - 75 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| PMID:35696490 | IVTH | 0.0000001 - 0.000001 M | 0.0000001 - 0.000001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 M | 0.0000001 M | Increased 21-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased estrone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.000001 M | 0.0000001 - 0.000001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.000001 M | 0.0000001 - 0.000001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.000001 M | 0.0000001 - 0.000001 M | Increased pregnenolone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.000001 M | 0.0000001 - 0.000001 M | Decreased Dehydroepiandrosterone (DHEA) levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.000001 M | 0.0000001 - 0.000001 M | Decreased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased 17-OH-pregnenolone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased 11-deoxycortisol level | Neurological endocrine-mediated perturbations | |
| PMID:37551828 | IVR | 2 - 4 ppm | 2 - 4 ppm | Decreased ovarian weights | Reproductive endocrine-mediated perturbations |
| IVR | 4 ppm | 4 ppm | Decreased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 4 ppm | 4 ppm | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 2 - 4 ppm | 2 - 4 ppm | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 4 ppm | 1 - 4 ppm | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 4 ppm | 4 ppm | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 4 ppm | 4 ppm | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 2 - 4 ppm | 2 - 4 ppm | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 4 ppm | 1 - 4 ppm | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 - 0.00001 M | 0.000001 - 0.00001 M | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:38423186 | IVTH | 0.000001 M | 0.000001 M | Decreased androstenedione levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Decreased estrone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased Dehydroepiandrosterone (DHEA) levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Alters aromatase activity | Reproductive endocrine-mediated perturbations | |
| PMID:38499550 | IVR | 1 ppm | 1 ppm | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 1 ppm | 1 ppm | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Hyperplasia in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:38901820 | IVTH | 0.000001 M | 0.000001 M | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| PMID:39136868 | IVTH | 0.00000001 - 0.00001 M | 0.00000001 - 0.00001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000003 - 0.000003 M | 0.0000003 - 0.000003 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:39210919 | IVR | 16 - 53.33 mg/kg/day | 16 - 53.33 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 16 - 53.33 mg/kg/day | 16 - 53.33 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.